Home > Healthcare > Medical Devices > Surgical Devices > Critical Limb Ischemia Treatment (CLI) Market

Critical Limb Ischemia Treatment (CLI) Market Trends

  • Report ID: GMI10560
  • Published Date: Aug 2024
  • Report Format: PDF

Critical Limb Ischemia Treatment Market Trends

Critical limb ischemia (CLI), a severe form of peripheral artery disease, leads to reduced blood flow to the limbs, causing pain, ulcers, and even the risk of limb amputation. Advances in medical technology have improved the outcomes of revascularization procedures, which are crucial in restoring blood flow and preventing limb loss.
 

  • The landscape for treating CLI has been revolutionized by the advent of minimally invasive revascularization techniques, like angioplasty and stent placement. These methods, utilizing catheters and small incisions, mitigate the risks associated with conventional open surgery. Their minimally invasive nature translates to quicker recovery, reduced postoperative pain, and diminished complication rates, rendering them appealing to both patients and healthcare providers.
     
  • Additionally, the precision of diagnosing CLI and planning revascularization procedures has been bolstered by advancements in vascular imaging technologies. Tools like duplex ultrasound, computed tomography angiography (CTA), and MRI systems offer detailed vascular images, aiding in accurately assessing blockage severity and location. These enhanced diagnostic capabilities not only streamline treatment planning but also lead to improved patient outcomes.
     
  • Furthermore, the introduction of drug-eluting stents and balloons has been a major innovation in the revascularization of CLI. These innovations, by dispensing medication directly into blood vessel walls, combat restenosis and elevate long-term patency rates. By curbing the necessity for repeat procedures, these drug-eluting technologies not only bolster the durability of treatment outcomes but also elevate patient quality of life, thereby fueling market growth.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The CLI industry was valued at USD 4.2 billion in 2023 and is anticipated to witness a CAGR of 6.7% through 2032, driven by the increasing prevalence of peripheral artery disease (PAD) coupled with growing awareness and early diagnosis.

The hospitals segment is anticipated to record a CAGR of 7% over 2024-2032, as this setting offers comprehensive care for CLI patients, including initial diagnosis, imaging, surgical interventions, and post-operative care.

North America critical limb ischemia treatment market size in 2023 was valued at USD 1.7 billion and is predicted to record a CAGR of 6.1% through 2032, attributed to the well-developed healthcare system, which provides broad access to advanced diagnostic and therapeutic technologies.

Boston Scientific, Cesca Therapeutics, Cook Medical, Eli Lilly and Company, Medtronic plc, Micro Medical Solutions, Pfizer, Sanofi, and Terumo Corporation among others.

Critical Limb Ischemia Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 215
  • Countries covered: 23
  • Pages: 110
 Download Free Sample